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ABSTRACT
Introduction. Attitudes of individuals who provide HIV care 
towards prescribing Preexposure Prophylaxis (PrEP) to at-risk 
populations have been studied, but few studies indicate if fam-
ily physicians would be willing to prescribe PrEP as most fam-
ily physicians do not specialize in HIV medicine. Few data ex-
ist on the perceived barriers preventing family physicians from 
prescribing PrEP.  The purpose of this project was to assess the 
attitudes and perceived barriers of family physicians in Kan-
sas towards prescribing PrEP to high risk patient populations.
Methods.XThis study was a descriptive, observational, 
and cross-sectional survey of family physicians who re-
spond to email surveys issued through the Family Medi-
cine Research and Data Information Office (FM RADIO). 
Results. Fifty-three percent of family physicians take a sex-
ual history on new patients less than frequently, and only 
35% frequently ask about the use of safe sex practices. Only 
29% frequently ask if the patient has sex with men, women, 
or both. Seventy-six percent of respondents would be will-
ing to prescribe PrEP to men who have sex with men, and an 
equal percentage would be willing to prescribe to heterosexu-
ally active men and women who are at substantial risk of ac-
quiring HIV. While 59% of participants agreed that PrEP be-
longs in the primary care domain of treatment, 71% agreed 
that they had limited or no knowledge of PrEP guidelines. 
Conclusions. This preliminary study indicated a need for in-
creased family physician screening of new patients for high risk 
sexual behaviors who would be eligible for PrEP. The limited 
knowledge of PrEP guidelines and its use in clinical practice 
are significant limiting factors to increasing prescribing prac-
tices in the family medicine community rather than a perceived 
ethical dilemma of prescribing PrEP to men who have sex with 
men. As a result, an increase in continuing medical educa-
tion about PrEP could significantly increase its prescribing in 
the family medicine community. KS J Med 2017;10(2):40-42.
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INTRODUCTION
Over 1.2 million people live with HIV in the United States, 
with 50,000 new infections diagnosed each year.1,2 The US Cen-
ters for Disease Control and Prevention (CDC) projects the 
lifetime risk of acquiring HIV nationally at 1 in 99.3 It is pro-
jected that 1 in 6 men who have sex with men (MSM) will ac-
quire HIV in their lifetime, which is over 70 times the lifetime 
risk of heterosexual men. The lifetime risk is highest in African 
American men who have sex with men (at nearly one in two) 
and lowest in in white men who have sex with men (one in 
eleven). In 2014, the CDC recommended the use of Truvada® 
(tenofovir disoproxil fumarate and emtricitabine) as a method 
to prevent HIV transmission for three patient populations if 
they have a substantial risk of acquiring HIV: men who have 
sex with men, IV drug users, and heterosexually active couples.4
HIV specialists noted that patients are more likely to seek care 
from a primary care physician to start PrEP therapy; thus PrEP 
may be managed more appropriately by primary care physi-
cians.5 We assessed if family physicians routinely screen for high 
risk sexual behaviors and if there are physician biases towards 
prescribing PrEP for MSM that prevent moving this preventa-
tive therapy into the family physician’s domain of treatment. 
METHODS
The study protocol was approved by the Institutional Review 
Board at the University of Kansas School of Medicine-Wichita. A 
confidential email survey was sent to the 85 members of a prac-
tice-based research network of family physicians in Kansas, the 
Family Medicine Research and Data Information Office (known 
as FM RADIO). The survey was sent with two follow-up emails 
for non-responders. Surveys were sent via SurveyMonkey® 
which provided a link to an online survey and allowed for an 
anonymous response. 
RESULTS
The response rate was 20 (23.5%). Sixteen respondents 
identified their sex; eleven (69%) were males. The average 
age of the respondents was 55 years with a range of 31 to 74 
years. Sixteen respondents revealed their practice county. 
Seven respondents practiced in a rural county (44%), six 
practiced in an urban county (38%), and three practiced 
in counties with a mid-sized regional community (19%).
Respondents revealed they were not familiar with the CDC 
Preexposure Prophylaxis (PrEP) for the Prevention of HIV 
practice guidelines.4 Of 18 respondents, only one (6%) was ex-
tremely familiar and seven (39%) were not familiar at all. Two 
of eighteen respondents (11%) had prescribed the recommend-
ed PrEP therapy and HIV antiretroviral medication Truvada®.
Table 1 reveals the respondents’ practices in taking a sexual 
history. As shown, few always take a sexual history on new 
patients. Few always ask important sexual history questions. 
Table 2 reveals survey responses related to the willingness to 
prescribe PrEP in certain patient populations. Most family 
physician respondents were willing to prescribe PrEP to their 
patients. Table 3 reveals barriers in prescribing PrEP therapy.
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Table 1. Selected responses to survey items related to sexual 
history practices (n, %). 
Survey Item Never Rarely Sometimes Frequently Always
I take a sexual 
history on all 
new patients 
(n = 19)
0 (0%) 4 (21%) 6 (32%) 6 (32%) 3 (16%)
I ask about the 
patient’s use of 
safe sex prac-
tices (n = 18).
1 (6%) 6 (33%) 5 (28%) 5 (28%) 1 (6%)
I ask if the 
patient has had 
multiple sexual 
partners in the 
last 6 months 
(n = 18)
1 (6%) 7 (39%) 5 (28%) 4 (22%) 1 (6%)
I ask if the 
patient has 
sex with men, 
women, or 
both. 
2 (11%) 7 (39%) 4 (22%) 3 (17%) 2 (11%)
Table 2. Respondents willingness to prescribe PrEP in certain 
patient populations (n, %). 
I would be willing to prescribe Truvada® for HIV Preexposure Pro-
phylaxis (PrEP) to the following patient population(s) if there are no 
contraindications (n = 17): 
Strongly 
Agree
Agree Neutral Disagree Strongly 
Disagree
Sexually active 
adult men who 
have sex with 
men (MSM) 
who are at sub-
stantial risk of 
HIV acquisition
8 (47%) 5 (29%) 2 (12%) 0 (0%) 2 (12%)
Heterosexually 
active men and 
women at sub-
stantial risk of 
HIV acquisition 
8 (47%) 5 (29%) 2 (12%) 0 (0%) 2 (12%)
Heterosexually 
active men and 
women whose 
partners have 
HIV infections 
to protect the 
uninfected 
partner during 
conception and 
pregnancy
10 (59%) 3 (18%) 3 (18%) 0 (0%) 1 (6%)
Table 3. Barriers to prescribing PrEP therapy (n, %). 
Barrier Strongly 
Agree
Agree Neutral Disagree Strongly 
Disagree
Limited or no 
knowledge of PrEP 
guidelines (n = 17)
8 (47%) 4 (24%) 4 (24%) 1 (6%) 0 (0%)
Concerned about 
side effects of Tru-
vada as a prophy-
lactic medication 
(n = 17)
1 (6%) 3 (18%) 11 (65%) 2 (12%) 0 (0%)
PreP therapy 
could increase the 
likelihood of sexu-
ally transmitted 
infections among 
men who have sex 
with men (n = 17)
1 (6%) 1 (6%) 7 (41%) 6 (35%) 2 (12%)
Patient adherence 
and compliance 
issues with PrEP 
will decrease its 
efficacy (n = 17)
0 (0%) 5 (29%) 8 (47%) 3 (18%) 1 (6%)
Prescribing will 
increase high risk 
sexual behaviors 
among men who 
have sex with men 
(n = 17)
1 (6%) 1 (6%) 5 (29%) 7 (41%) 3 (18%)
Will decrease 
safe sex practices 
among men who 
have sex with men 
(n = 17)
1 (6%) 3 (18%) 4 (24%) 8 (47%) 1 (6%)
Stigma or backlash 
in the office 
1 (6%) 0 (0%) 3 (18%) 11 (65%) 2 (12%)
Limited time or re-
sources for patient 
education about 
PrEP therapy (n 
= 17)
1 (6%) 6 (35%) 8 (47%) 2 (12%) 0 (0%)
Do not want 
to prescribe a 
medication that 
requires lab work 
and follow-up 
every 3 months (n 
= 17)
0 (0%) 3 (18%) 9 (53%) 4 (24%) 1 (6%)
Perceived moral 
and/or ethical di-
lemma prescribing 
PrEP to men who 
have sex with men 
(n = 16)
0 (0%) 2 (13%) 3 (19%) 8 (50%) 3 (19%)
Eleven of eighteen respondents (61%) agreed that PrEP be-
longs in the primary care domain of treatment. Only four (22%) 
agreed that PrEP belongs only in the HIV specialist’s domain. 
Eighty-two percent stated they would be willing to prescribe 
PrEP with more education and training. Ten of 17 respondents 
(59%) agreed that PrEP should be covered by private insurance.
Table 4 reveals the conditions when family physician respon-
dents would be willing to prescribe PrEP. Most respondents 
(70%) would be willing with PrEP education and training.
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Table 4. Conditions when respondents would be willing to 
prescribe PrEP (n = 20). 
Condition n (%)
I received PrEP education and training 14 (70%)
PrEP is covered by private insurance 5 (25%)
I know other family physicians prescribe PrEP 7 (35%)
I did not have to prescribe it to men who have sex 
with men
1 (5%)
I read research that demonstrates its efficacy in HIV 
prevention
7 (35%)
Under no circumstances would I prescribe PrEP 
therapy
1 (5%)
DISCUSSION
This preliminary study indicated a need for increased fam-
ily physician screening of new patients for high risk sexual 
behaviors who would be eligible for PrEP. In our sample, no 
apparent bias was noted against prescribing PrEP for men who 
have sex with men, as survey participants were equally will-
ing to prescribe Truvada® to MSM and heterosexual couples 
at high risk for acquiring HIV. Based on the study results, the 
limited knowledge of PrEP guidelines and their use in clinical 
practice are significant limiting factors to increasing prescrib-
ing practices in the family medicine community rather than a 
perceived ethical dilemma of prescribing Truvada® to men who 
have sex with men. Yet, it is difficult to assess the “true” will-
ingness for family physicians to prescribe a medication that 
a significant number are unfamiliar with. As a result, an in-
crease in continuing medical education about Truvada® could 
increase its prescribing in the family medicine community.
The strengths of the study include a mixture of both urban 
and rural participants in communities with varying popula-
tions. The small sample size may be due to the controversial 
nature of the topic which may have shifted the responses to-
wards a more positive side if those who disagreed abstained 
from the survey, thereby, reflecting a potential sampling bias. 
Even with only two study participants not willing to prescribe 
PrEP, this could be significant in rural areas as there are few pri-
mary care physicians available. There is an estimated 3,333 indi-
viduals living with HIV in Kansas as of December 2013, which is 
likely lower than other geographic regions in the United States 
and could limit physician exposure to HIV management and 
education on the topic.6 Further, the lack of awareness of PrEP 
guidelines as shown by the survey responses may have decreased 
participation in a cohort known to respond to survey requests.
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